MX2022003939A - Composicion farmaceutica de estabilidad mejorada. - Google Patents

Composicion farmaceutica de estabilidad mejorada.

Info

Publication number
MX2022003939A
MX2022003939A MX2022003939A MX2022003939A MX2022003939A MX 2022003939 A MX2022003939 A MX 2022003939A MX 2022003939 A MX2022003939 A MX 2022003939A MX 2022003939 A MX2022003939 A MX 2022003939A MX 2022003939 A MX2022003939 A MX 2022003939A
Authority
MX
Mexico
Prior art keywords
lactate
conjugate
pharmaceutical composition
based polymer
less
Prior art date
Application number
MX2022003939A
Other languages
English (en)
Inventor
Yuhua Li
Andrew J Guarino
Original Assignee
Yuhua Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhua Li filed Critical Yuhua Li
Publication of MX2022003939A publication Critical patent/MX2022003939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición inyectable para la administración de fármacos por liberación controlada y el proceso de fabricación del mismo, donde la composición comprende: un polímero a base de lactato que tiene un peso molecular promedio en peso de entre 5.000 y 50.000 dalton, un número ácido menor de 3 mg de KOH/g y un contenido de monómeros de lactida residual en el polímero a base de lactato menor de aproximadamente 0,3% en peso; un solvente orgánico farmacéuticamente aceptable; y una sustancia bioactiva o una sal de la misma que contiene un aminoácido serina en su estructura molecular, que es capaz de reaccionar con el monómero lactida para formar un conjugado; y donde la composición reduce la formación del conjugado.
MX2022003939A 2014-10-15 2017-04-21 Composicion farmaceutica de estabilidad mejorada. MX2022003939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462064008P 2014-10-15 2014-10-15

Publications (1)

Publication Number Publication Date
MX2022003939A true MX2022003939A (es) 2022-04-25

Family

ID=55747307

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005235A MX2017005235A (es) 2014-10-15 2015-10-15 Composición farmacéutica de estabilidad mejorada.
MX2022003939A MX2022003939A (es) 2014-10-15 2017-04-21 Composicion farmaceutica de estabilidad mejorada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005235A MX2017005235A (es) 2014-10-15 2015-10-15 Composición farmacéutica de estabilidad mejorada.

Country Status (20)

Country Link
US (2) US20160106804A1 (es)
EP (1) EP3207149B1 (es)
JP (2) JP6717839B2 (es)
KR (2) KR102274420B1 (es)
CN (2) CN113209009A (es)
AU (2) AU2015332456A1 (es)
BR (1) BR112017007669A2 (es)
CA (1) CA2964475C (es)
ES (1) ES2949827T3 (es)
HR (1) HRP20230716T1 (es)
HU (1) HUE062326T2 (es)
IL (1) IL251703B (es)
MX (2) MX2017005235A (es)
NZ (1) NZ730538A (es)
PL (1) PL3207149T3 (es)
RS (1) RS64339B1 (es)
RU (1) RU2728786C2 (es)
SA (1) SA517381298B1 (es)
SG (1) SG11201702535QA (es)
WO (1) WO2016061296A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
CA3048499A1 (en) * 2017-01-04 2018-07-12 Pharmathen S.A. Process for preparing biodegradable polymers of high molecular weight
KR20190110567A (ko) * 2017-01-31 2019-09-30 베루 인코퍼레이티드 성선 자극 호르몬-방출 호르몬(GnRH) 길항제의 장기간 방출을 위한 조성물 및 방법
US20200282008A1 (en) * 2017-01-31 2020-09-10 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
EP3727421A4 (en) * 2017-12-18 2021-07-28 Foresee Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITIONS WITH A CHOSEN DISCHARGE DURATION
BR112024002231A2 (pt) 2021-08-05 2024-04-30 Medincell S A Composição farmacêutica

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0572675B1 (en) 1991-12-19 1999-09-22 Mitsui Chemicals, Inc. Polyhydroxy carboxylic acid and production thereof
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
FR2776516B1 (fr) * 1998-03-25 2001-05-25 Pharma Biotech Compositions presentant une liberation prolongee et leur procede de preparation
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
PT1158014E (pt) 1998-12-15 2005-04-29 Takeda Pharmaceutical Processo para a producao de poliesteres biodegradaveis
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
DK1824460T3 (en) 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
KR101466933B1 (ko) * 2006-07-11 2014-12-01 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
PL2115029T3 (pl) * 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów
WO2009064442A1 (en) * 2007-11-13 2009-05-22 Brookwood Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
CN102958512B (zh) 2008-08-29 2015-04-29 健赞股份有限公司 控释肽制剂
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
EP3207149A1 (en) 2017-08-23
KR102134873B1 (ko) 2020-07-17
RS64339B1 (sr) 2023-08-31
JP2017531697A (ja) 2017-10-26
JP6717839B2 (ja) 2020-07-08
EP3207149B1 (en) 2023-06-07
JP6928695B2 (ja) 2021-09-01
CN107075541A (zh) 2017-08-18
ES2949827T3 (es) 2023-10-03
AU2019279929A1 (en) 2020-01-16
AU2015332456A1 (en) 2017-04-13
US20220160817A1 (en) 2022-05-26
CA2964475A1 (en) 2016-04-21
US20160106804A1 (en) 2016-04-21
EP3207149A4 (en) 2018-06-13
MX2017005235A (es) 2019-12-11
SG11201702535QA (en) 2017-04-27
RU2017111079A3 (es) 2019-05-17
HUE062326T2 (hu) 2023-10-28
RU2728786C2 (ru) 2020-07-31
WO2016061296A1 (en) 2016-04-21
KR20190029783A (ko) 2019-03-20
CN107075541B (zh) 2021-06-25
KR102274420B1 (ko) 2021-07-08
CA2964475C (en) 2020-03-24
SA517381298B1 (ar) 2021-12-18
PL3207149T3 (pl) 2023-08-21
IL251703A0 (en) 2017-06-29
RU2017111079A (ru) 2018-11-15
HRP20230716T1 (hr) 2023-10-13
AU2019279929B2 (en) 2021-02-25
NZ730538A (en) 2024-01-26
BR112017007669A2 (pt) 2017-12-19
CN113209009A (zh) 2021-08-06
KR20170070176A (ko) 2017-06-21
EP3207149C0 (en) 2023-06-07
IL251703B (en) 2021-03-25
JP2020147595A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MX2023006541A (es) Formulaciones de dosis fija.
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
RS54024B1 (en) GASTRORETENCY FORMULATION OF MEDICINES AND SYSTEMS FOR DELIVERY AND METHODS OF THEIR PREPARATION USING FUNCTIONALIZED CALCIUM CARBONATE
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
SG194175A1 (en) Polymer conjugated prostaglandin analogues
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MX2019000381A (es) Formulacion para la administracion de arn.
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
NZ727834A (en) Fast acting orally disintegrating film
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
MX2019005775A (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
MX2016004660A (es) Composiciones de peptido novedosas.
WO2012010938A3 (en) Pharmaceutical composition of cefditoren pivoxil
WO2016027160A3 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
WO2016055111A8 (en) Amphiphilic copolymers their preparation and use for the delivery of drugs
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form
MX2017016978A (es) Composicion farmaceutica de heparinas de bajo peso molecular.
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
MX2014003939A (es) Sistema farmaceutico para la administracion oral de sustancias terapeuticas sensibles.
UA111566C2 (uk) Фармацевтична композиція пролонгованого вивільнення морфолінію [(5-метил-1н-1,2,4-триазол-3-іл)тіо]ацетату